CD47+ CD133+ CSCs may possess stronger self‐protection capability.6, 9, 29, 30 In ovarian, breast and pancreatic cancers, blockade CD47 signaling making CSCs more susceptible to be eliminated by macrophages.15, 17 All observations above suggest that CD47 can be a potential target for removing CSCs, thus preventing tumor relapse post‐conventional cytoreductive therapies. This evidence concerns the gene CD47 and familial pancreatic carcinoma.